Your browser is no longer supported. Please, upgrade your browser.
Settings
GTHX [NASD]
G1 Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.56 Insider Own0.70% Shs Outstand42.12M Perf Week4.71%
Market Cap662.59M Forward P/E- EPS next Y-3.59 Insider Trans-33.46% Shs Float38.57M Perf Month13.17%
Income-102.90M PEG- EPS next Q-0.99 Inst Own70.60% Short Float19.78% Perf Quarter-25.78%
Sales64.00M P/S10.35 EPS this Y19.80% Inst Trans1.70% Short Ratio7.54 Perf Half Y-31.41%
Book/sh5.06 P/B3.07 EPS next Y0.60% ROA-38.40% Target Price- Perf Year-0.58%
Cash/sh5.73 P/C2.72 EPS next 5Y- ROE-49.40% 52W Range10.81 - 37.07 Perf YTD-13.56%
Dividend- P/FCF- EPS past 5Y-27.10% ROI-49.60% 52W High-58.05% Beta2.17
Dividend %- Quick Ratio10.30 Sales past 5Y144.10% Gross Margin98.40% 52W Low43.85% ATR0.70
Employees122 Current Ratio10.40 Sales Q/Q214.30% Oper. Margin- RSI (14)54.58 Volatility6.42% 4.79%
OptionableYes Debt/Eq0.14 EPS Q/Q-13.30% Profit Margin- Rel Volume2.60 Prev Close14.27
ShortableYes LT Debt/Eq0.14 EarningsAug 04 AMC Payout- Avg Volume1.01M Price15.55
Recom1.70 SMA206.69% SMA50-3.71% SMA200-24.75% Volume2,628,824 Change8.97%
Nov-17-20Downgrade Raymond James Strong Buy → Outperform
Jun-26-20Initiated ROTH Capital Buy $55
Jan-21-20Reiterated H.C. Wainwright Buy $72 → $82
Aug-08-19Upgrade JP Morgan Neutral → Overweight
Feb-07-19Initiated B. Riley FBR Buy $55
Jan-23-19Downgrade JP Morgan Overweight → Neutral
Dec-20-18Initiated Raymond James Strong Buy
Nov-08-18Reiterated Needham Buy $76 → $74
Sep-10-18Resumed BTIG Research Buy $80
May-29-18Initiated H.C. Wainwright Buy $61
May-18-18Reiterated Needham Buy $42 → $60
Sep-15-21 06:45AM  
Sep-03-21 07:45AM  
07:30AM  
Aug-08-21 03:27AM  
Aug-05-21 10:00AM  
03:31AM  
Aug-04-21 05:15PM  
04:01PM  
08:00AM  
Aug-02-21 06:50AM  
Jul-28-21 03:04PM  
08:00AM  
Jul-19-21 09:20AM  
Jul-15-21 04:05PM  
Jul-06-21 04:23AM  
Jul-02-21 07:30PM  
Jun-18-21 09:00AM  
Jun-16-21 07:00AM  
Jun-14-21 07:00AM  
Jun-04-21 04:01PM  
09:02AM  
09:01AM  
May-21-21 03:34AM  
May-19-21 05:01PM  
May-17-21 07:00AM  
May-10-21 06:50AM  
May-07-21 04:01PM  
May-06-21 04:30AM  
May-05-21 06:20PM  
04:01PM  
02:45PM  
Apr-28-21 10:00AM  
07:00AM  
Apr-26-21 09:42AM  
Apr-07-21 07:00AM  
Apr-06-21 05:14AM  
Apr-02-21 04:05PM  
Apr-01-21 07:30AM  
Mar-25-21 06:50AM  
Mar-24-21 08:50AM  
04:00AM  
Mar-05-21 04:05PM  
Mar-03-21 07:30AM  
Mar-02-21 06:59AM  
Feb-25-21 12:00AM  
Feb-24-21 05:23PM  
04:01PM  
02:30PM  
Feb-17-21 08:00AM  
Feb-14-21 08:10AM  
04:07AM  
Feb-12-21 07:41PM  
Feb-04-21 11:55PM  
07:30AM  
Jan-26-21 03:22PM  
Jan-11-21 06:30AM  
Jan-05-21 07:00AM  
Jan-04-21 07:00AM  
Dec-31-20 11:57PM  
Dec-14-20 09:56AM  
Dec-09-20 05:00PM  
Nov-30-20 10:30AM  
Nov-29-20 12:30PM  
Nov-24-20 07:00AM  
Nov-18-20 07:00AM  
Nov-15-20 08:18AM  
Nov-11-20 07:01AM  
Nov-08-20 07:56AM  
Nov-05-20 08:39AM  
Nov-04-20 09:32PM  
04:31PM  
04:01PM  
02:30PM  
Oct-28-20 07:01AM  
Oct-15-20 07:00AM  
Sep-30-20 04:01PM  
Sep-14-20 07:00AM  
Sep-02-20 07:01AM  
Aug-17-20 06:00AM  
Aug-05-20 04:01PM  
Aug-04-20 07:00AM  
Aug-03-20 07:00AM  
Jul-29-20 07:01AM  
Jul-23-20 08:25AM  
Jul-22-20 06:00PM  
Jun-30-20 04:36PM  
04:10PM  
Jun-22-20 06:00AM  
Jun-18-20 12:27PM  
Jun-16-20 07:09AM  
Jun-11-20 08:36AM  
Jun-01-20 04:01PM  
May-13-20 05:31PM  
May-07-20 10:30AM  
May-06-20 04:01PM  
07:36AM  
Apr-29-20 07:00AM  
Apr-07-20 07:00AM  
Mar-13-20 07:12AM  
Mar-12-20 08:05AM  
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer, as well as Phase II clinical trials for the treatment of neoadjuvant breast cancer; lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a collaboration with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment of locally advanced breast cancer; and license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Velleca Mark A.DirectorJul 15Option Exercise0.3910,0003,90071,000Jul 15 04:01 PM
Velleca Mark A.DirectorJul 15Sale18.4910,000184,89861,000Jul 15 04:01 PM
Velleca Mark A.DirectorJul 14Option Exercise0.3910,0003,90071,000Jul 15 04:01 PM
Velleca Mark A.DirectorJul 14Sale19.0810,000190,82461,000Jul 15 04:01 PM
Velleca Mark A.DirectorJul 13Option Exercise0.3910,0003,90071,000Jul 15 04:01 PM
Velleca Mark A.DirectorJul 13Sale19.4510,000194,53661,000Jul 15 04:01 PM
Velleca Mark A.DirectorJun 17Option Exercise0.3910,0003,90071,000Jun 17 04:05 PM
Velleca Mark A.DirectorJun 17Sale21.7710,000217,72861,000Jun 17 04:05 PM
Velleca Mark A.DirectorJun 16Option Exercise0.3910,0003,90071,000Jun 17 04:05 PM
Velleca Mark A.DirectorJun 16Sale21.7410,000217,38461,000Jun 17 04:05 PM
Velleca Mark A.DirectorJun 15Option Exercise0.3910,0003,90071,000Jun 17 04:05 PM
Velleca Mark A.DirectorJun 15Sale22.3910,000223,90961,000Jun 17 04:05 PM
Velleca Mark A.DirectorMay 25Option Exercise0.3920,0007,80061,000May 25 06:29 PM
Velleca Mark A.DirectorMay 13Option Exercise0.3910,0003,90051,000May 13 04:43 PM
Velleca Mark A.DirectorMay 13Sale20.5410,000205,41341,000May 13 04:43 PM
Velleca Mark A.DirectorMay 12Option Exercise0.3910,0003,90051,000May 13 04:43 PM
Velleca Mark A.DirectorMay 12Sale20.0710,000200,69141,000May 13 04:43 PM
Velleca Mark A.DirectorMay 11Option Exercise0.3910,0003,90051,000May 13 04:43 PM
Velleca Mark A.DirectorMay 11Sale19.1010,000190,99741,000May 13 04:43 PM
Malik RajeshChief Medical OfficerMay 10Option Exercise0.3010,0003,00053,300May 11 04:23 PM
Malik RajeshChief Medical OfficerApr 22Option Exercise0.3915,0005,85058,300Apr 23 04:39 PM
Malik RajeshChief Medical OfficerApr 22Sale22.0715,000331,10043,300Apr 23 04:39 PM
Velleca Mark A.DirectorApr 15Option Exercise0.3910,0003,90051,000Apr 15 05:53 PM
Velleca Mark A.DirectorApr 15Sale24.9610,000249,63141,000Apr 15 05:53 PM
Velleca Mark A.DirectorApr 14Option Exercise0.3910,0003,90051,000Apr 15 05:53 PM
Velleca Mark A.DirectorApr 14Sale24.5310,000245,27241,000Apr 15 05:53 PM
Velleca Mark A.DirectorApr 13Option Exercise0.3910,0003,90051,000Apr 15 05:53 PM
Velleca Mark A.DirectorApr 13Sale23.8910,000238,86541,000Apr 15 05:53 PM
Malik RajeshChief Medical OfficerMar 23Option Exercise0.3915,0005,85058,300Mar 24 04:47 PM
Malik RajeshChief Medical OfficerMar 23Sale21.9415,000329,06043,300Mar 24 04:47 PM
Moses Jennifer K.CFOMar 03Option Exercise3.723,00011,16025,000Mar 04 04:54 PM
Malik RajeshChief Medical OfficerMar 02Option Exercise1.5515,00023,21958,300Mar 04 05:10 PM
Malik RajeshChief Medical OfficerMar 02Sale22.9515,000344,19243,300Mar 04 05:10 PM
Velleca Mark A.DirectorFeb 18Option Exercise3.7210,00037,20051,000Feb 18 05:49 PM
Velleca Mark A.DirectorFeb 18Sale26.0210,000260,15241,000Feb 18 05:49 PM
Velleca Mark A.DirectorFeb 17Option Exercise3.7210,00037,20051,000Feb 18 05:49 PM
Velleca Mark A.DirectorFeb 17Sale27.6410,000276,43341,000Feb 18 05:49 PM
Velleca Mark A.DirectorFeb 16Option Exercise3.7211,04041,06952,040Feb 18 05:49 PM
Velleca Mark A.DirectorFeb 16Sale35.2011,040388,65341,000Feb 18 05:49 PM
Malik RajeshChief Medical OfficerJan 27Option Exercise0.393,1001,20943,300Jan 29 04:07 PM
Malik RajeshChief Medical OfficerJan 22Option Exercise4.1715,00062,55055,200Jan 22 06:47 PM
Malik RajeshChief Medical OfficerJan 22Sale20.6415,000309,59140,200Jan 22 06:47 PM
Velleca Mark A.DirectorJan 21Option Exercise3.7210,00037,20051,000Jan 21 05:31 PM
Velleca Mark A.DirectorJan 21Sale20.6410,000206,40041,000Jan 21 05:31 PM
Velleca Mark A.DirectorJan 20Option Exercise2.7714,00038,76047,000Jan 21 05:31 PM
Velleca Mark A.DirectorJan 20Sale21.5110,000215,10737,000Jan 21 05:31 PM
Velleca Mark A.DirectorJan 19Option Exercise3.7210,00037,20047,000Jan 21 05:31 PM
Velleca Mark A.DirectorJan 19Sale20.8810,000208,78137,000Jan 21 05:31 PM
RUDNICK SETHDirectorDec 24Sale20.1092418,5725,266Dec 29 04:50 PM
RUDNICK SETHDirectorDec 23Sale20.1813,118264,7576,190Dec 23 06:54 PM
RUDNICK SETHDirectorDec 22Sale20.3318,974385,70219,308Dec 23 06:54 PM
Velleca Mark A.President and CEODec 17Option Exercise3.7210,00037,20047,000Dec 17 06:01 PM
Velleca Mark A.President and CEODec 17Sale19.9710,000199,66837,000Dec 17 06:01 PM
Velleca Mark A.President and CEODec 16Option Exercise3.7210,00037,20047,000Dec 17 06:01 PM
Velleca Mark A.President and CEODec 16Sale19.2010,000192,02137,000Dec 17 06:01 PM
Velleca Mark A.President and CEODec 15Option Exercise3.7210,00037,20047,000Dec 17 06:01 PM
Velleca Mark A.President and CEODec 15Sale19.4310,000194,29737,000Dec 17 06:01 PM
Malik RajeshCh. Medical Officer & SVP R&DDec 10Option Exercise4.179,00037,53038,200Dec 11 04:50 PM
Malik RajeshCh. Medical Officer & SVP R&DDec 10Sale20.069,000180,55029,200Dec 11 04:50 PM
RUDNICK SETHDirectorDec 10Sale20.0054610,92138,282Dec 10 05:30 PM
RUDNICK SETHDirectorDec 09Sale20.325,773117,28438,828Dec 10 05:30 PM
RUDNICK SETHDirectorDec 08Sale20.1913,161265,69444,601Dec 10 05:30 PM
RUDNICK SETHDirectorDec 01Sale20.0952010,44957,762Dec 03 04:20 PM
MUIR GLENN PDirectorNov 18Buy13.5050,000675,000170,969Nov 19 04:54 PM
Bailey John E. (Jack) Jr.DirectorNov 11Buy12.834,00051,3208,000Nov 13 04:33 PM
Bailey John E. (Jack) Jr.DirectorNov 10Buy12.764,00051,0554,000Nov 13 04:33 PM